D.E. Shaw & Co’s Fate Therapeutics FATE Stock Holding History

D.E. Shaw & Co’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$1.94M	–	5449
2022 Q1	$1.94M	Buy	+50,000	New	+$1.94M	﹤0.01%	3333

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co's FATE Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 433,192 shares — an estimated $342K sold.

D.E. Shaw & Co first reported a position in FATE in Q1 2018 and held it in 20 quarters. The position peaked at $36M in Q4 2020. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

D.E. Shaw & Co reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
D.E. Shaw & Co sold 433,192 Fate Therapeutics shares in Q2 2025, an estimated $342K.
D.E. Shaw & Co first reported a position in Fate Therapeutics in Q1 2018 and held it in 20 quarters.
D.E. Shaw & Co's Fate Therapeutics position peaked at $36M in Q4 2020.
139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.